In the only phase 3 trial of gene therapy for hemophilia completed and published to date (of valoctocogene roxaparvovec), the primary endpoint was the change from baseline in median FVIII activity during weeks 49–52, assessed using the CSA [62,63]. This evidence concerns the gene F8 and hemophilia.